Institute of Biomedical Technologies

Chronic kidney disease, diabetes and kidney transplant complications

INVESTIGADORES RESPONSABLES

Esteban Porrini, MD, PhD

(“Ramón y Cajal” Investigator, Department of Internal Medicine, Dermatology and Psychiatry, ULL
Armando Torres Ramírez, MD, PhD

Professor of Medicine, Department of Internal Medicine, Dermatology and Psychiatry, ULL – Head of Nephrology Service, HUC

CLINICAL COLLABORATORS:

  • Alejandra Álvarez, MD (HUC)
  • Ana González Rinne, MD (HUC)
  • Beatriz Escamilla, MD (HUC)
  • Domingo Marrero Miranda, MD (HUC)
  • Lourdes Pérez Tamajón, MD (HUC)
  • Patricia Delgado Mallen, MD (HUC)
  • Sara Estupiñán, MD (HUC)

EXTERNAL POSTDOCTORAL COLLABORATORS:

  • Sergio Luis Lima, PhD (RedInRen Contracted Investigator, ISCIII)
  • Ana Elena Rodríguez Rodríguez, PhD (Contracted Investigator FGULL)
  • Javier Donate Correa, PhD (ISCIII “Sara Borrell” Programme, FIISC)
  • Marian Cobo Caso, PhD (HUC)
  • Rosa Miquel, PhD (HUC)

PHD STUDENTS AND TRAINEES:

  • Raúl Morales Febles: Exercise and prediabetes after transplantation (PFIS 17/00303)
  • Carlos González Alayón: Estimated and measured GFR in cirrhosis
  • Pablo Jorge Pérez: Estimated and measured GFR in acute heart failure
  • Germán Pérez Suárez: Evolution of bone mineral density and prevalence of renal lithiasis in adult patients diagnosed with idiopathic hypercalciuria in childhood (“Evolución de la densidad mineral ósea y prevalencia de litiasis renal en pacientes adultos diagnosticados de hipercalciuria idiopática en la infancia”)

TECHNICAL AND ADMINISTRATIVE STAFF:

  • Federico González Rinne (Informatician UCICEC-HUC)
  • Natalia Negrín Mena (Contracted Research Network RedInRen, ISCIII)

RESEARCH LINES:

Our aim is to study strategies to prevent the deterioration of kidney function in chronic kidney disease (CKD), and the metabolic and cardiovascular complications associated with kidney transplants. We analyse the impact of diabetes, obesity, metabolic syndrome and insulin resistance on CKD.

Regarding kidney transplantation, we concentrate on the study of post-transplantation diabetes and pre-diabetes. We are interested in epidemiological studies as a proof of concept for randomised clinical trials, and in the use of animal models to study new preventive effects of immunosuppressant drugs with pro-diabetic actions.

FUNDED PROJECTS:

  • Loss of kidney function in the absence of proteinuria in type 2 diabetic women (PI16/01814 – La pérdida de la función renal en ausencia de proteinuria en mujeres con diabetes tipo 2”). PI: Esteban Porrini. Institute of Health Carlos III (2017-2020, 113,437.50 €).
  • Pre-donation kidney reserve: impact on the donor and receptor kidney function in a live donor kidney transplant programme (PIFUN18/17 – “Reserva renal predonación: impacto en la evolución de la función renal del donante y receptor en un programa de trasplante renal de donante vivo”). PIs: Ana González Rinne and Esteban Porrini. The Canary Islands Foundation for Medical Research, FUNCANIS (2018-2020, 30,000 €).
  • National “Ramón y Cajal” programme. Postdoctoral contracts for Research and Development centres (RYC-2014-16573. “Diabetic Nephropathy, Post-transplant diabetes”). PI: Esteban Porrini. MINECO (Ramón y Cajal Sub-programme; 2015-2020, 268.600 € -salary, 5 years+ 40,000 €, Research Project).
  • REDINREN Kidney research Network: Transplant Program II. (RD16/0009/0031- “Red Temática de Investigación Renal REDINREN: Programa II Trasplante”). PI: Armando Torres. Institute of Health Carlos III (2017-2021, 102,300 €).
  • New mechanisms of diabetogenicity for immunosuppressant drugs related to FKBP12 binding, the loss of B-cell identity and changes in insulin secretion (PI16/02151 – “Nuevos mecanismos de diabetogenicidad de los inmunosupresores relacionados con su unión a FKBP12 pérdida de identidad de la célula beta y cambios en la secreción de insulina”). PI: Armando Torres. Institute of Health Carlos III (2017-2021, 121,302.50 €).
  • The role of inflammation on prediabetes and diabetes alter renal transplantation; the beneficial effect of moderate exercise. (PI19/01187). PI: Armando Torres. Institute of Health Carlos III (2019-2022, 62,315 €).
  • Testing the efficacy of a flavonoid in renal disease. PI: Esteban Porrini. ARAFARMA (2019-2021, 90,000 €).
  • Relationship between renal function to endothelial dysfunction in living donors, CONFUCIUS study. PI: Francisco Moreso / Esteban Porrini. TEVA laboratory (2018-2020, 46,000 €).
  • Unmasking progressors towards chronic kidney disease in Autosomal Dominant Polycystic Kidney Disease (ADPKD) by measured renal function. Co-PI: Esteban Porrini. OTSUKA laboratory (2017-2020, 25,000 €).
  • Efficacy of ENVARSUS in the prevention of PTDM. PI: Armando Torres. Co-PI: Esteban Porrini. Chiesi laboratory (2018-2021, 59.000 €).
  • Preclinical development of a new drug for the treatment of hyperuricemia and hyperuremia (“Desarrollo preclínico de un nuevo fármaco para el tratamiento de la hiperuricemia e hiperuremia”: Exp. Matriz 19120187). PIs: Araceli Delgado, Esteban Porrini. Arafarma Group S.A., FGULL (2019-2020, 199,870 €).

PUBLICATIONS 2019:

  • Rodriguez-Rodriguez A, Donate-Correa J, Rovira J, Cuesto G, Luis-Ravelo D, Fernandes MX, Acevedo-Arozena A, Diekmann F, Acebes A, Torres A, Porrini E. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by Tacrolimu Am J Transplant. 2019 Dec;19(12):3240-3249. doi: 10.1111/ajt.15483
  • Fernandez-Fernandez B, Fernandez-Prado R ,Górriz JL,Martinez-Castelao A, Navarro-González JF,Porrini E,Soler MJ,Ortiz A.Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: What was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? Clin Kidney J. 2019 May 31;12(3):313-321. doi: 10.1093/ckj/sfz070
  • Porrini E,Ruggenenti P,Luis-Lima S,Carrara F,Jiménez A,de Vries APJ,Torres A,Gaspari F,Remuzzi G. Estimated GFR: time for a critical appraisal. Nat Rev Nephrol. 2019 Mar;15(3):177-190. doi: 10.1038/s41581-018-0080-9
  • Sarafidis P,Ferro CJ,Morales E,Ortiz A,Malyszko J,Hojs R,Khazim K,Ekart R, Valdivielso J,Fouque D,London GM,Massy Z,Ruggenenti P,Porrini E,Wiecek A, Zoccali C,Mallamaci F,Hornum M SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407
  • Luis-Lima S,Escamilla-Cabrera B,Negrín-Mena N,Estupiñán S,Delgado-Mallén P,Marrero-Miranda D,González-Rinne A,Miquel-Rodríguez R, Cobo-CasoMÁ,Hernández-Guerra M, Oramas J, Batista N,Aldea-Perona A,Jorge-Pérez P,González-Alayón C,Moreno-Sanfiel M,González-Rodríguez JA,Henríquez L, Alonso-Pescoso R,Díaz-Martín L,González-Rinne F,Lavín-Gómez BA,Galindo-Hernández J,Sánchez-Gallego M,González-Delgado A,Jiménez-Sosa A,Torres A,Porrini E. Chronic kidney disease staging with cystatin C or creatinine-based formulas: Flipping the coin. Nephrol Dial Transplant. 2019 Feb 1;34(2):287-294. doi: 10.1093/ndt/gfy086
  • Bettiga A,Fiorio F,Di Marco F,Trevisani F,Romani A,Porrini E,Salonia A,Montorsi F, Vago R.The modern western diet rich in advanced glycation end-products (AGEs): An overview of its impact on obesity and early progression of renal pathology. 2019 Jul 30;11(8). pii: E1748. doi: 10.3390/nu11081748
  • González-Rinne A,Luis-Lima S,Escamilla B,Negrín-Mena N,Ramírez A,Morales A, Vega N,García P,Cabello E,Marrero-Miranda D, Aldea-Perona A,Alvarez A, Abad MDC,Pérez-Tamajón L,González-Rinne F,González-Delgado A,Díaz Martín L, Jiménez-Sosa A,Torres A,Porrini E. Impact of errors of creatinine and cystatin C equations in the selection of living kidney donors. Clin Kidney J. 2019 Mar 18;12(5):748-755. doi: 10.1093/ckj/sfz012
  • Porrini E,Díaz JM,Moreso F,Lauzurrica R,Ibernon M,Torres IS,Ruiz RB,Rodríguez Rodríguez AE,Mallén PD,Bayés-Genís B,Gainza FJ,Osorio JM,Osuna A, Domínguez R, Ruiz JC,Sosa AJ,Rinne AG, Miranda DM,Macías M,Torres A. Prediabetes is a risk factor for cardiovascular disease following renal transplantation. Kidney Int. 2019 Dec;96(6):1374-1380. doi: 10.1016/j.kint.2019.06.026
  • Luis-Lima S, Higueras Linares T, Henríquez-Gómez L, Alonso-Pescoso R, Jimenez A, López-Hijazo AM, Negrín-Mena N, Martín C, Sánchez-Gallego M, Galindo Hernández SJ, Socas Fernández Del Castillo R, Castilla-Marrero M, Domínguez Coello S, Vilchez de León V, Valcárcel-Lopez R, Insausti-Garmendia N, Escamilla B, Estupiñán S, Delgado-Mallén P, Armas-Padrón AM, Marrero-Miranda D, González-Rinne A, Miquel Rodríguez RM, Cobo-Caso MA, Díaz-Martín L, González-Rinne F, González-Delgado A, López-Martínez M, Jiménez-Sosa A, Torres A, Porrini E. The Error of Estimated GFR in Type 2 Diabetes Mellitus. J Clin Med. 2019 Sep 26;8(10). pii: E1543. doi: 10.3390/jcm8101543
  • López-Martínez M, Luis-Lima S, Morales E, Navarro-Díaz M, Negrín-Mena N, Folgueras T, Escamilla B, Estupiñán S, Delgado-Mallén P, Marrero-Miranda D, González-Rinne A, Miquel-Rodríguez RM, Cobo-Caso MA, Díaz-Martín L, Jiménez Sosa A, González-Rinne F, Torres A, Porrini E. The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors. Int J Obes (Lond). 2019 Oct 22. doi: 10.1038/s41366-019-0476-z. [Epub ahead of print]

OTHER SELECTED PUBLICATIONS FROM THE LAST 10 YEARS:

  • Porrini E, Díaz JM, Moreso F, Delgado Mallén PI, Silva Torres I, Ibernon M, Bayés- Genís B, Benitez-Ruiz R, Lampreabe I, Lauzurrica R, Osorio JM, Osuna A, Domínguez-Rollán R, Ruiz JC, Jiménez-Sosa A, González-Rinne A, Marrero-Miranda D, Macía M, García J, Torres A. Clinical evolution of post-transplant diabetes mellitus. Nephrol Dial Transplant. 2016 Mar;31(3):495-505. doi:10.1093/ndt/gfv368
  • Luis-Lima S, Rodríguez-Rodríguez AE, Martin-Higueras C, Sierra-Ramos C, Carrara F, Arnau MR, de la Rosa DA, Salido E, Gaspari F, Porrini E. Iohexol plasma clearance, a simple and reliable method to measure renal function in conscious mice. Pflugers Arch. 2016 Sep;468(9):1587-94. doi: 10.1007/s00424-016-1843-4
  • D’Agati VD, Chagnac A, de Vries AP, Levi M, Porrini E, Herman-Edelstein M, Praga M. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016 Aug;12(8):453-71. doi: 10.1038/nrneph.2016.75
  • Porrini E, Ruggenenti P, Mogensen C-E et al., for the ERA-EDTA Working Group Diabesity. A role for non-proteinuric pathways in loss of renal function in patients with type 2 diabetes? Lancet Diabetes Endocrinol. 2015 May;3(5):382-91. doi: 10.1016/S2213-8587(15)00094-7
  • Luis-Lima S, Gaspari F, Porrini E, Garcia-Gonzalez M, Batista N, Bosa-Ojeda F, Oramas J, Carrara F, Gonzalez-Posada JM, Marrero D, Salido E, Torres A, Jimenez-Sosa A. Measurement of glomerular filtration rate: Internal and external validations of the iohexol plasma clearance technique by HPLC. Clin Chim Acta. 2014 Mar 20;430:84-5. doi:10.1016/j.cca.2013.12.028
  • de Vries AP,Ruggenenti P,Ruan XZ,Praga M,Cruzado JM,Bajema IM,D’AgatiVD,Lamb HJ,Pongrac Barlovic D,Hojs R,Abbate M,Rodriquez R,MogensenCE,Porrini E;ERA-EDTA Working Group Diabesity. Fatty kidney: emerging role of ectopic lipid in obesityrelated renal disease. Lancet Diabetes Endocrinol. 2014 May;2(5):417-26. doi: 10.1016/S2213-8587(14)70065-8
  • Rodríguez-Rodríguez AE, Trinanes J, Velázquez-García S, Porrini E, Vega Prieto MJ, Diez Fuentes ML, Arevalo M, Salido Ruiz E, Torres A. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean zucker rats. Am J Transplant. 2013 Jul;13(7):1665-75. doi: 10.1111/ajt.12236
  • Triñanes J, Rodriguez-Rodriguez AE, Brito-Casillas Y, Wagner A, De Vries APJ, Cuesto G, Acebes A, Salido E, Torres A, Porrini E. Deciphering Tacrolimus-Induced Toxicity in Pancreatic β Am J Transplant. 2017 Nov;17(11):2829-2840. doi:10.1111/ajt.14323